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g.2013.0Abstract The correct identiﬁcation of the genes involved in ESBL mediated resistance is necessary
for the surveillance and epidemiological studies of their transmission in hospitals. The aim of the
present study was to ﬁnd the prevalence of ESBL producing Klebsiella pneumoniae among K. pneu-
moniae isolates separated from Egyptian patients with suspected nosocomial infections, to detect
their drug resistance pattern and to look for bla SHV and bla CTX-M genes in such organisms.
Subjects andmethods: 138K. pneumoniae isolates from Egyptian patients with suspected nosocomial
infections were screened for ESBL production by the pattern of antimicrobial susceptibilities. Phe-
notypic identiﬁcation for ESBL production was conﬁrmed by double disc synergy test, phenotypic
conﬁrmatory double disc test and by MicroScan panel system. bla SHV and bla CTX-M genes in
ESBL producing K. pneumoniae were detected using multiplex PCR. Results: The prevalence of
ESBL producing K. pneumoniae was 21% (30/138). Their pattern of antimicrobial susceptibility
showed that 90% was resistant to (Sulphamethoxazole/Trimethoprim), 70% was resistant to
(Amoxicillin/Clavulanate), 63.3% was resistant to Cefotaxime and Ceftazidime, 60% was resistant
to Amikacin, 46.7% was resistant to Doxycycline, Cefoxitin, Ceftriaxone and Levoﬂoxacin, 40%
was resistant to Cefepime, 20% was resistant to Ertapenem and (Sulbactam/Cefoperazone),
13.3% was resistant to (Piperacillin/Tazobactam), 10% was resistant to (Imipenem/Cilastatin)
and Gentamycin and 6.7% was resistant to Meropenem and Ciproﬂoxacin. Among the ESBL pro-
ducing K. pneumoniae, three out of 30 (10%) and 16 out of 30 (53.3%) were positive for bla SHV
and bla CTX-M genes respectively.
It could be concluded that ESBL producing isolates ofK. pneumoniae have been increasingly rec-
ognized in the hospital settings in Egypt and are associated with multiple drug resistance. Thus,01979035.
com (O.I. Ahmed).
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demiological investigation of their transmission in hospitals and antimicrobial resistance.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.Figure 1 Double disc synergy test using discs of CTX30 =
Cefotaxime 30 lg, CAZ30 = Ceftazidime 30 lg, CRO30 = Cef-
triaxone 30 lg, AMC30 = Amoxyclav 30 lg.1. Introduction
Extended spectrum or third generation cephalosporins e.g.
Cefotaxime, Ceftazidime, and Ceftriaxone were introduced
into clinical use in the early 1980s to provide effective therapy
largely for nosocomial infections caused by multi-resistant and
especially Gentamycin resistant Enterobacteriaceae, particu-
larly Klebsiella spp., Enterobacter spp. and Pseudomonas
aeruginosa [1]
Extended-spectrum beta-lactamases (ESBLs) are a heter-
ogeneous group of plasmid-mediated bacterial enzymes that
confer signiﬁcant resistance to oxyimino-cephalosporin and
monobactam antimicrobials [2]. Resistance to cephalospo-
rins has become widespread throughout the world, and
numerous types of ESBLs have been detected in various
bacterial organisms [3]. Various authors have reported the
prevalence of ESBLs to be in the range of 6–88% in var-
ious hospitals [4], especially among Klebsiella pneumoniae
and Escherichia coli.
Systemic infections with ESBL producing Enterobacteria-
ceae are associated with severe adverse clinical outcomes
[5]. It is thus essential for a diagnostic microbiology labora-
tory to have updated methods for the detection of ESBL-
producing strains, taking into account the local epidemiol-
ogy of ESBL genotypes and their various expression pro-
ﬁles [6].
Extended-spectrum beta-lactamases arise mainly due to
mutations in b-lactamases encoded by the bla SHV, bla
TEM, and bla CTX-M genes. More than 300 different ESBL
variants have been described [7]. Though TEM and SHV vari-
ants are the most common ESBLs, during the past decade,
strains expressing CTX-M ESBLs have begun to emerge in
many countries [8] and are now the most frequent non-TEM,
non-SHV ESBL type. CTX-M b-lactamases are characterized
by selective hydrolysis of cefotaxime rather than Ceftazidime,
though some CTX-M types, such as CTX-M-15, may actually
hydrolyse Ceftazidime [9].
Detection of ESBLs is primarily based on phenotypic
testing, such as evidencing a synergy image using the dou-
ble-disc synergy test performed with expanded-spectrum
cephalosporins and ticarcillin–clavulanic acid discs [10,11].
This test is not always obvious and is usually time-consum-
ing since it requires subculturing or the use of cloxacillin-
containing plates to inhibit the naturally occurring and
plasmid-mediated cephalosporinases [12]. Over the last
20 years, alternative strategies aimed at replacing or com-
plementing traditional phenotypic methods have been pro-
posed. Standard PCR and gene sequencing is still the
most widely used technique [13,14].
The aim of the present study was to ﬁnd the prevalence
of ESBL producing K. pneumoniae among K. pneumoniae
isolates separated from Egyptian patients with suspected
nosocomial infections, to detect their drug resistance pat-
tern and to look for bla SHV and bla CTX-M genes in
such organisms.2. Patients and methods
One hundred and thirty-eight K. pneumoniae isolates from dif-
ferent clinical specimens (blood, sputum, urine, pus aspirates
and endotracheal secretions) were collected over three months
from patients with suspected nosocomial infections in a ter-
tiary care hospital. Specimens were collected and cultured on
blood agar (Oxoid Ltd., Basingstoke, UK) and MacConkey
agar (Difco/BD Diagnostics Systems, Sparks, MI, USA) ex-
cept for urine samples which were plated on Cysteine Lactose
Electrolytes Deﬁcient (CLED) agar. All isolatedK. pneumoniae
strains were identiﬁed in the clinical samples by conventional
microbiological methods (colonial morphology, Gram stain-
ing, and biochemical tests) according to Collee et al. [15].
Initial screening for ESBL was done by the pattern of anti-
microbial susceptibilities. Phenotypic identiﬁcation of ESBL
production was conﬁrmed by double disc synergy test, and
phenotypic conﬁrmatory double disc test according to CLSI
guidelines [16] and by MicroScan panel system.
2.1. Antimicrobial susceptibility testing and initial ESBL
identiﬁcation
Isolates were tested for the pattern of antimicrobial susceptibil-
ities by an agar disc diffusion method using paper discs (AB
Biodisk, Solna, Sweden) on Mueller–Hinton (MH) agar
including susceptibility to the following antibiotics: Amikacin,
(Amoxicillin/Clavulanate), Cefepime, (Cefoperazone/Sulbac-
tam), Cefotaxime, Cefoxitin, Ceftazidime, Ceftriaxone, Cipro-
ﬂoxacin, Doxycycline, Ertapenem, Gentamycin, (Imipenem/
Cilastatin), levoﬂoxacin, Meropenem, (Piperacillin/Tazobac-
tam) and (Sulfamethoxazole/Trimethoprim). After overnight
incubation at 37 C, inhibition zone diameters were read.
The results of a disc diffusion test are interpreted by compar-
ing the measured zone diameter with the interpretive criteria
recommended by CLSI guidelines [16].
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The organism to be tested was spread onto a Mueller–Hinton
agar plate. The antibiotic discs used were Ceftriaxone (30 lg),
Cefotaxime (30 lg), Ceftazidime (30 lg), and Amoxycillin/
Clavulanic acid (20/10 lg). The three antibiotics were placed
at distances of 30 mm (edge to edge) from the Amoxycillin/
Clavulanic acid disc that was placed in the middle of the plate.
After 24-h incubation, if an enhanced zone of inhibition be-
tween either of the Cephalosporin antibiotics and the Amoxy-
cillin/Clavulanic acid disc occurred, the test was considered
positive. This indicated synergistic activity with Clavulanic
acid and the presence of an ESBL (Fig. 1).
2.1.2. Phenotypic conﬁrmatory disc diffusion test (combined disc
method) [18]
A Ceftazidime (30 lg) disc was used alone and in combination
with Clavulanic acid (30 lg/10 lg) for phenotypic conﬁrma-
tion of the presence of ESBLs. A P5 mm increase in zone
diameter for either of the Cephalosporin discs and their respec-
tive Cephalosporin/Clavulanate disc was interpreted as ESBL
producer (Fig. 2)
2.1.3. MicroScan panel identiﬁcation (ID) and antimicrobial
susceptibility testing (AST)
The MicroScan WalkAway 96 SI System (Dade Behring, CA)
identiﬁcation and antimicrobial susceptibility testing were per-
formed with Neg BP combo panel type 30. All procedures were
performed according to the manufacturer’s recommendations.
The screening of ESBL-producing microorganisms and inter-
pretation were based on rules contained within the LabPro Ex-
pert system (version 2.0), which uses growth in the presence of
Cefpodoxime (4 lg/ml) and Ceftazidime (1 lg/ml) at concen-
trations recommended by the CLSI [16] for ESBL screening.
The MicroScan panel MIC-based Clavulanate synergy test
was used for conﬁrmation of the presence of ESBLs.
Antibiotic susceptibilities were determined by overnight
microdilution, with commercial dehydrated panels provided
by (Dade Behring, CA). The ESBL plus panels were prepared
and inoculated according to the manufacturer’s recommended
procedures. The inoculated panels were then placed into the
MicroScan WalkAway instrument for incubation, ﬁnal read-Figure 2 Phenotypic conﬁrmatory disc diffusion test using
Ceftazidime disc 30 lg and Ceftazidime/Clavulanate disc 30/
10 lg. P5 mm increase in zone diameter for antimicrobial agent
tested in combination with Clavulanate versus its zone when tested
alone = ESBL.ing and interpretation of the results, which was conducted
according to CLSI guidelines [16]. The following antimicrobial
agents (concentration ranges in mg/L) were used in the Micro-
Scan ESBL plus panel: Aztreonam, 0.5–16; Cefepime, 1–32;
Cefotetan, 1–32; Cefpodoxime, 0.5–64; Cefotaxime, 0.5–128;
Cefotaxime/Clavulanate, 0.125/4–16/4; Cefoxitin, 2–32; Ceft-
azidime, 0.5–128; Ceftazidime/Clavulanate, 0.125/4–16/4; Cef-
triaxone, 1–64; Imipenem, 0.5–16; Meropenem, 0.5–16;
Piperacillin, 16–64.
2.2. Multiplex PCR for detection of bla SHV and bla CTX-M
genes
2.2.1. Preparation of plasmid DNA
Plasmid DNA was isolated from a single colony of each isolate
according to Jemima and Verghese [19] using Gen Jet Plasmid
Miniprep Kit Cat. No. K0502 (Fermentas, Thermo scientiﬁc,
France).
2.2.2. Multiplex PCR
The Multiplex PCR was done to identify bla SHV and bla
CTX-M genes simultaneously. The sequences of primers used
for detection of bla SHV gene were: 50ATT TGT CGC TTC
TTT ACT CGC-30 as a forward primer and 50 TTT ATG
GCG TTA CCT TTG ACC-30 as a reverse primer. The two
primers included a 1018 bp fragment. For detection of bla
CTX-M gene, the sequences of primers used were 50-ATG
TGC AGY ACC AGT AAR GT 30 as a forward primer and
50-TGG GTR AAR TAR GTS ACC AGA 30 as a reverse pri-
mer. The two primers included a 544 bp fragment [19].
PCR was performed in a DNA thermal cycler (Biometra,
Germany) using the kit Maxima Hot Start PCR Master Mix
(2·), Cat. No. K1051 (Fermentas, Thermo scientiﬁc, France),
according to the manufacturer’s instructions. It is a ready-to-
use mix containing Maxima hot start Taq DNA polymerase,
optimized hot start PCR buffer, Mg Cl2, and dNTPs. The
reaction was performed in a 50-ll volume containing 25 ll
Maxima hot start PCR master mix (2·), the primers (1 lM
each), together with one ug of the extracted DNA. Nuclease
free water was used to complete 50 ll volumes.
Ampliﬁcation proﬁle was done according Jemima and
Verghese [19]. Positive and negative controls were ampliﬁed
with each run. After gel electrophoresis, the ethidium bromide
stained PCR products were visualized under UV light. The size
of the bands were compared to the molecular weight marker,
Gene Ruler 1 Kb plus DNA ladder Cat. No. SM1331
(Fermentas, Thermo scientiﬁc, France).3. Results
From the 138K. pneumoniae isolates, 30 were ESBL producing
(21%) that were obtained from 30 clinical samples as follows:
11 (36.7%) from sputum, 3 (10%) from urine, 6 (20%) from
blood, 5 (16.7%) from pus aspirates, and 5 (16.7%) from
endotracheal secretions.
The pattern of antimicrobial susceptibility among the 30
ESBL producing K. pneumoniae showed that 90% was resis-
tant to (Sulfamethoxazole/Trimethoprim), 70% was resistant
to (Amoxicillin/Clavulanate), 63.3% was resistant to Cefotax-
ime and Ceftazidime, 60% was resistant to Amikacin, 46.7%
Table 1 Pattern of antimicrobial susceptibility in ESBL producing Klebsiella pneumoniae isolates separated from patients (N= 30).
Sensitivity Sensitive Intermediate Resistant
Name of antibiotic disc No. of isolates % No. of isolates % No. of isolates %
Amikacin 12 40 – 18 60
Amoxicillin/Clavulanate 4 13.3 5 16.7 21 70
Cefepime 12 40 6 20 12 40
Cefoperazone/Sulbactam 17 56.7 7 23.3 6 20
Cefotaxime 5 16.7 6 20 19 63.3
Cefoxitin 12 40 4 13.3 14 46.7
Ceftazidime 5 16.7 6 20 19 63.3
Ceftriaxone 5 16.7 11 36.6 14 46.7
Ciproﬂoxacin 24 80 4 13.3 2 6.7
Doxycycline 11 36.6 5 16.7 14 46.7
Ertapenem 20 66.7 4 13.3 6 20
Gentamycin 18 60 9 30 3 10
Imipenem/Cilastatin 24 80 3 10 3 10
Levoﬂoxacin 15 50 1 3.3 14 46.7
Meropenem 24 80 4 13.3 2 6.7
Piperacillin/Tazobactam 15 50 11 36.7 4 13.3
Sulfamethoxazole/Trimethoprim 2 6.7 1 3.3 27 90
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oﬂoxacin, 40% was resistant to Cefepime, 20% was resistant
to Ertapenem and (Cefoperazone/Sulbactam), 13.3% was
resistant to (Piperacillin/Tazobactam), 10% was resistant to
(Imipenem/Cilastatin), and Gentamycin and 6.7% was resis-
tant to Meropenem and Ciproﬂoxacin (Table 1).
Multiplex PCR detection of bla SHV and bla CTX-M genes
in ESBL producingK. pneumoniae showed that among the clin-
ical isolates, 63.3% of isolates carried one of the two genes.
Three out of 30 (10%) isolates were positive for bla SHV gene,
giving a 1018 bp band, while 16 out of 30 (53.3%) isolates were
positive for bla CTX-M gene. Isolates that were positive to bla
SHV gene were different from those that were positive to bla
CTX-M gene (Fig. 3).
4. Discussion
The spread of ESBL-producing bacteria has been strikingly ra-
pid worldwide, indicating that continuous monitoring systems
and effective infection control measures are absolutely re-
quired. Therapeutic options for infections due to ESBL pro-
ducers have also become increasingly limited. Health care
interactions including the use of antibiotics, particularly oxyi-
minocephalosporins and hospital transfer are among well-Figure 3 Gel electrophoresis of the PCR products of bla CTX-M ge
ladder, lanes numbered 1, 2, 3, 4, 5, 6, 7, 8 show 544 bp bands of PCdeﬁned risk factors for acquisition of ESBL-producing bacte-
ria [20].
Molecular detection and identiﬁcation of beta lactamases
would be essential for a reliable epidemiological investigation
of antimicrobial resistance. These enzymes can be chromo-
somal or plasmid mediated. The gene code for the enzymes
may be carried on integrons. Integrons help in the dissemina-
tion of antimicrobial drug resistance in health care settings.
Therefore, ESBL producing organisms should be identiﬁed
quickly so that appropriate antibiotic usage and infection con-
trol measures can be implemented [21].
The present study was conducted on 30 ESBL producing
K. pneumoniae isolates that were obtained from 30 clinical
samples isolated from patients admitted to a tertiary care
hospital and have suspected nosocomial infections. The
clinical samples were 11 (36.3%) sputum, 6 (20%) blood,
5 (16.7%) pus aspirates, 5 (16.7%) endotracheal secretions
and 3 (10%) urine. El sherif and Maamoun [22] performed
a study on isolates with the ESBL phenotype in a hospital
in Egypt, that were obtained from various clinical speci-
mens: 34% was isolated from urine cultures, 21.5% from
sputum, 17% from blood culture, 13% from wounds,
10% from stool of healthy carrier and 4.5% from broncho-
alveolar lavages. However, in that study, 41.5% of isolatesne. First lane, molecular weight marker; Gene Ruler 1Kbp DNA
R products while lane number 9 shows negative result.
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the remaining 58.5% was from inpatients.
In the present study, the ESBL producing K. pneumoniae
isolates were 21% (30/138) of all K. pneumoniae collected over
a period of three months. In comparison with the rest of the
world, there is generally a lack of comprehensive data regard-
ing ESBL-producing Enterobacteriaceae in African countries.
However, there is sufﬁcient evidence to highlight the preva-
lence of ESBLs in Africa. It is recognized that Egypt has an ex-
tremely high rate of ESBL producers, with up to 70% of
isolates producing the enzyme [23]. An outbreak was reported
in a neonatal intensive care unit in Cairo, Egypt, in which 80%
of the isolates were K. pneumoniae, of which 58% was ESBL
producers [24].
Some studies reported high percentages of ESBL producing
organisms, Feizabadi et al. [25] found that among 89 K. pneu-
moniae isolates, the phenotypic conﬁrmatory test detected 62
isolates (69.7%) as ESBL-producing K. pneumoniae. Also,
Lal et al. [26] in India found that 86% of Klebsiella isolates
were found to be resistant to at least one of the third genera-
tion cephalosporins, of which 97.1% was conﬁrmed to be po-
sitive for ESBL. Another study from north India reported the
prevalence of ESBL as 66.7% in K. pneumoniae isolates [27].
And, Rodriques et al. [28] have reported that 53% of the nos-
ocomial Gram-negatives were found to be ESBL producers.
On the other hand, other studies reported low percentages
of ESBL producing organisms, Chong et al. [29] found that
K. pneumoniae with ESBL production were 4.9% of total K.
pneumoniae isolated in a Japanese hospital. And, Kumar
et al. [30] from Hyderabad, India, reported that 19.8% of
Enterobacteriaceae species isolated over a period of one year
were ESBL producers.
The prevalence of ESBL-expressing bacteria varies across
different geographical regions. Fewer than 10% of isolated
strains express ESBLs in Sweden, Japan and Singapore, com-
pared to rates higher than 30% in Portugal, Italy, New York
and some Latin American countries. In Turkey, as many as,
58% of isolated strains express ESBLs [7].
In the present study, the pattern of antimicrobial suscepti-
bilities was studied in all ESBL producing K. pneumoniae iso-
lates and showed that 90% was resistant to (Sulfamethoxazole/
Trimethoprim), 70% was resistant to (Amoxicillin/Clavula-
nate), 63.3% was resistant to Cefotaxime and Ceftazidime,
60% was resistant to Amikacin, 46.7% was resistant to Doxy-
cycline, Cefoxitin, Ceftriaxone and levoﬂoxacin, 40% was
resistant to Cefepime, 20% was resistant to Ertapenem and
(Cefoperazone/Sulbactam), 13.3% was resistant to (Piperacil-
lin/Tazobactam), 10% was resistant to (Imipenem/Cilastatin),
and Gentamycin and 6.7% was resistant to Meropenem and
Ciproﬂoxacin. In agreement with the present study, Chong
et al. [29] found that the ESBL-producing bacteria were resis-
tant to almost all generations of cephalosporins but remained
highly susceptible to carbapenems which is consistent with the
resistance pattern of organisms with ESBLs [31].
Feizabadi et al. [25] studied 89 K. pneumoniae isolates and
found that all strains were susceptible to imipenem and the
rates of resistance to different antibiotics were in the following
order: Aztronam (79.7%), Cefexime (67.4%), Cefpodoxime
(66.2%), Cefotaxime (65.1%), Ceftazidime (61.7%) while,
Morosini et al. [32] mentioned that most ESBL-producing
strains, particularly those with the TEM, SHV, and CTX-M
genotypes, are resistant to aminoglycosides.In the present study, 63.3% of ESBL producingK. pneumo-
niae carried one of the two genes. Among the clinical isolates, 3
out of 30 (10%) isolates were positive for bla SHV gene while
16 out of 30 (53.3%) isolates were positive for bla CTX-M
gene. Isolates that were positive to bla SHV gene were different
from those that were positive to bla CTX-M gene.
El sherif and Maamoun [22] studied 77 isolates of Klebsiella
spp. with the ESBL phenotype for detection of the four genes
of bla (TEM, SHV, CTX-M, and OXA) using multiplex PCR.
SHV gene was found in 45.5% of Klebsiella spp. and CTX-M
was found in 44% of Klebsiella spp. And, Chong et al. [29]
found that among 20 ESBL K. pneumoniae, TEM/SHV were
found in 4 (20%), CTX-M 0 (0%) and TEM/SHV+ CTX-
M 16 (80%) while, Khalaf et al. [33] mentioned that the
CTX-M genotype appeared to be the most common type in
North Africa. And, it has been known for their rapid spread
in Europe and Asia [34].
Kiratisin et al. [35] noticed increasing trends in the preva-
lence of CTX-M ESBLs. They found that a total of 87.3%
of ESBL-producing isolates carried several bla genes. The
prevalence of bla CTX-M was strikingly high: 99.2% for
ESBL-producing K. pneumoniae which carried bla SHV at
87.4%. Thus, they concluded that CTX-M ESBL is highly en-
demic in Thailand. Previous survey in Thailand from 1994 to
1996 revealed that, among 32 isolates of ESBL-producing
E. coli and ESBL-producing K. pneumoniae, bla SHV was
the most predominant while bla CTX-M was not detected
[36]. The ﬁrst detection of bla CTX-M in Thailand was docu-
mented from a study of 48 Enterobacteriaceae isolates recov-
ered during 1998 and 1999, where the prevalence of bla
CTX-M was 52% and subsequently increased to 65% among
52 isolates collected in 2003 [37].
Jemima and Verghese [19] performed multiplex PCR for
detection of bla CTX-M and bla SHV in 62 ESBL positive
Klebsiella spp. Results showed that bla SHV like genes were
found in 45% and bla CTX-M genes were found in 40% of
Klebsiella spp. Also, Sekar et al. [38] reported the prevalence
of bla CTX-M gene in 14/39 selected clinical Gram negative
isolates in India.
However, low percentage of CTX-M gene was reported in
other study. Tofteland et al. [6] studied 25 clinical isolates of
K. pneumoniae in Norway with reduced susceptibilities to oxyi-
mino-cephalosporins for bla TEM/SHV/CTX-M ESBL genes.
An ESBL phenotype was recognized in 84% of K. pneumoniae
isolates expressing reduced susceptibility to an expanded-
spectrum cephalosporin by the E test and combined disc meth-
od. Bla CTX-M was reported in three cases, bla SHV in 15
cases and bla TEM was detected in only one case.
Higher percentages of SHV gene were reported in other
studies, Feizabadi et al. [25] detected the genes encoding the
ESBLs including bla SHV and bla CTX-M among 89 K. pneu-
moniae isolates by PCR. The prevalence of bla SHV was
67.4% and bla CTX-M-I was 46.51% and bla CTX-M-III
was 29%. Lal et al. [26] randomly selected 95 Klebsiella iso-
lates for PCR of TEM and SHV genes. Isolates having both
TEM and SHV genes were common (67.3%) whereas only
20% isolates possessed TEM gene and 8.4% SHV gene alone.
And, Grover et al. [39] in India reported that bla TEM and bla
SHV alone or together were present in 88.8% of the Klebsiella
isolates in their study.
It could be concluded that ESBL producing isolates of K.
pneumoniae have been increasingly recognized in the hospital
282 O.I. Ahmed et al.settings in Egypt as well as throughout the world. Moreover,
multiple resistances to antimicrobials are apparent. Thus,
molecular identiﬁcation of the genes encoding beta lactamases
would be essential for a reliable epidemiological investigation
of their transmission in hospitals and antimicrobial resistance.
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